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Introduction
Erectile dysfunction (ED) constitutes an increasing health 
problem in the aging male population.1 The prevalence of 
ED is age-dependent, affecting up to 86% of men >80 
years. A total of 150 million men are affected worldwide.2,3 
ED may be indicative of other underlying cardiovascular 
diseases and thus is mostly associated with traditional car-
diovascular risk factors.4
Arterial insufficiency is the leading cause of ED and may 
result from obstructions of the common and internal iliac 
arteries as well as the pudendal and penile arteries.5 It was 
recently shown that the pudendal artery is the single most 
frequent arterial segment to be affected by atherosclerotic 
obstructions in patients with ED of arterial origin.6 In that 
study, the average pudendal arterial diameter was very 
comparable to the average coronary artery diameter. In 
patients with ED attributed to arterial disease, endovascular 
therapy constitutes promising results to restore blood flow 
and improve clinical outcomes.5,7,8 However, the ideal 
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Abstract
Purpose: To evaluate the incidence of elastic recoil in patients presenting with erectile dysfunction (ED) undergoing 
endovascular revascularization of the pudendal or penile arteries. Methods: A consecutive series of 21 ED patients (mean 
age 58.3±9.3 years) undergoing minimally invasive revascularization of 31 arteries was analyzed. ED lesions included the 
pudendal arteries (n=27) and the penile artery (n=4). Mean lesion length was 20.6±13.9 mm. Minimal lumen diameter 
(MLD) measurements were assessed at baseline, immediately after balloon angioplasty, and 10 minutes thereafter. Early 
recoil was defined as an MLD reduction >10%. Elastic recoil with >10% lumen compromise was treated with drug-coated 
balloons, while severe elastic recoil (>30%) required drug-eluting stents (DES). The International Index of Erectile Function 
(IIEF-15) score was obtained prior to and 3 months after the procedure to obtain information on functional outcomes 
subsequent to angioplasty. Results: Mean MLD at baseline was 0.9±0.6 mm, which improved to 2.0±0.9 mm immediately 
after balloon dilation. At 10 minutes after dilation, the MLD was 1.7±1.0 mm. Elastic recoil was observed in all 31 lesions 
and resulted in a mean lumen compromise of 21.2%. Severe (>30%) recoil was observed in 14 arteries, which underwent 
DES therapy. The IIEF-15 score improved from 31.3±11.2 at baseline to 49.8±16.8 (p<0.001) at the 3-month follow-up. 
Conclusion: Endovascular revascularization constitutes a safe and feasible treatment modality to restore erectile function 
in patients with arteriogenic ED and ineffective conservative management. Early elastic recoil is very frequent subsequent 
to balloon dilation of small-caliber erection-related arteries. Thus, mechanical scaffolding with DES is required in a high 
subset of ED patients to provide favorable early angiographic and clinical results.
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antirestenotic regimen within this challenging arterial seg-
ment remains to be determined.7
Given that ED with arterial obstructions of oftentimes 
small-caliber erection-related arteries may be present even 
in comparatively young patients, a “leave nothing behind 
strategy” with drug-coated balloon (DCB) angioplasty may 
be a favorable treatment option. On the other hand, mechan-
ical scaffolding with stents is regarded as necessary in other 
small-caliber arteries (eg, coronary or tibial).9,10 Thus, prior 
to a clinical investigation aimed at finding the ideal antire-
stenotic therapy in pudendal artery obstructions, an assess-
ment of early elastic recoil, an important contributor to 
restenosis in coronary or tibial arteries,9,10 is warranted.
The purpose of the present study was to analyze the 
prevalence of elastic recoil subsequent to balloon angio-
plasty in ED patients undergoing endovascular therapy. 
This information may provide further guidance on optimiz-
ing endovascular treatment strategies in ED patients.
Methods
Study Design and Baseline Examination
This was a prospective investigation of 21 consecutive ED 
patients (mean age 58.3±9.3 years) unresponsive to phospho-
diesterase-5 (PDE-5) inhibitor who had endovascular revascu-
larization between March and August 2017. All patients 
underwent hormonal examination to exclude hypothalamic-
pituitary and/or gonadal disorder, as well as thyroid dysfunc-
tion. Duplex ultrasound examination was performed in all 
patients to rule out venous leakage, defined as an end-diastolic 
velocity >0.15 m/s indicating a dysfunction of the veno-occlu-
sive mechanism.7 Arterial diagnostics included duplex ultra-
sound subsequent to the intracavernosal administration of 10 
mg of prostaglandin E1 (alprostadil). In case of pathological 
arterial flow on penile duplex ultrasound (peak systolic veloc-
ity <0.3 m/s),11 computed tomography angiography (CTA) of 
the iliac and pudendal arteries was performed to document 
arteriogenic ED (lumen compromise >50%) prior to endovas-
cular revascularization. The assessed cardiovascular risk fac-
tors were defined as outlined elsewhere.12 The International 
Index of Erectile Function13 (IIEF-15) score was obtained 
from all patients at baseline and during follow-up at 3 months.
Ethics committee approval for the present study was 
waived since the procedures conformed to the standard of 
care in our center following earlier experiences with small-
vessel angioplasty.9
Angiographic Imaging and Measurements
Single plane digital subtracted angiograms captured on 
an Artis Q system (Siemens, Erlangen, Germany) were 
analyzed on a PACS workstation (Siemens) by an inter-
ventional angiologist with 9 years of endovascular expe-
rience (N.D.). A stenosis was defined as a lumen 
compromise ⩾50%. Lesion length was measured as the 
distance of ⩾50% lumen compromise for stenoses or as 
the distance over an occlusion to the point of where the 
artery reconstituted. Reference vessel diameters (RVD) 
and minimal lumen diameters (MLD) were measured 
using an automated edge detection system (Siemens). 
MLD was assessed at baseline, immediately subsequent to 
angioplasty, and 10 minutes thereafter. Elastic recoil was 
defined as lumen compromise >10% and calculated as: [1 
– (lumen gain at 15 minutes / lumen gain after dilation)] × 
100.9 Accordingly, severe elastic recoil was defined as a 
lumen compromise >30% 10 minutes after dilation.
Endovascular Revascularization
All procedures were performed under local anesthesia 
with retrograde puncture of the contralateral common 
femoral artery. After insertion of a 6-F sheath (Terumo 
Destination, Terumo, Japan), the common iliac artery was 
catheterized by crossover access to obtain angiographic 
imaging of the iliac arteries using a single-curve RIM 
catheter. Heparin (5000 units) was administered in all 
patients. Thereafter, the hypogastric and pudendal arteries 
were engaged under roadmap guidance with a 0.014-inch 
guidewire. Nitroglycerine was injected selectively into the 
target artery over the RIM catheter and over the 6-F sheath 
at the origin of the internal pudendal artery for selective/
superselective angiography. Lesions of erection-related 
arteries were angiographically imaged in different projec-
tions and quantitatively analyzed. After crossing the lesion 
with a 0.014-inch guidewire (Figure 1), balloon dilation 
was performed with a standardized inflation time of 1 
minute at nominal inflation pressure. Balloon diameters 
were chosen based on artery diameter measurements.
Angiography was repeated 10 minutes after the end of 
dilation. If elastic recoil >10% but ⩽30% was detected, 
DCB angioplasty was performed using Sequent Please 
paclitaxel-coated balloons (B. Braun, Berlin, Germany). 
The RVD to DCB diameter ratio was 1.01. If recoil at 10 
minutes after dilation was >30%, a DES was implanted 
(Coroflex ISAR; B. Braun). Care was taken not to oversize 
the diameter of the DCB or DES beyond 10% of the RVD. 
In patients with multiple lesions, all lesions were consis-
tently treated with either DCB or DES.
After endovascular therapy, all patients received dual 
antiplatelet therapy for 12 months (aspirin 100 mg/d plus 
clopidogrel 75 mg/d). In addition, tadalafil 5 mg daily was 
prescribed for 3 weeks subsequent to the intervention.
Patient Population
Stenotic lesions were identified in 31 arteries (27 pudendal 
arteries, 3 dorsal penile arteries, and 1 common penile artery). 
Four of the 21 patients presented with elevated end-diastolic 
velocities (>0.15 m/s) on duplex ultrasound, indicating 
Diehm et al 3
concomitant venous occlusive disease. Patient characteristics 
are provided in Table 1 and angiographic findings in Table 2. 
Mean lesion length was 20.6±13.9 mm. Lesions involving 
the penile arteries were shorter compared with the pudendal 
artery lesions (4.0 vs 23.0 mm).
Clinical Outcomes
The primary endpoint was elastic recoil after balloon angio-
plasty; secondary endpoints included target lesion (TLR) and 
target vessel revascularization (TVR). In addition, the course 
of symptoms was assessed by administering the IIEF-15 ques-
tionnaire at baseline and 3 months after endovascular therapy; 
scores on 2 specific questions were compared: Question 3 
[When you attempted intercourse, how often were you able to 
penetrate (enter) your partner?] and Question 4 [During sex-
ual intercourse, how often were you able to maintain your 
erection after you had penetrated (entered) your partner?].
The primary safety endpoints were puncture site com-
plications and major adverse events at 30 days, defined as 
device- or procedure-related death, perineal gangrene or 
necrosis (glans penis, penile shaft, scrotal, or anal), or the 
need for subsequent perineal, penile, or anal surgery 
(including TLR, TVR, or arterial embolization).
Statistical Analysis
Continuous variables were expressed as means ± standard 
deviation. Differences were compared using an indepen-
dent t test for parametric and the Wilcoxon rank sum test for 
nonparameteric variables. Categorical variables were 
reported as the numbers and compared using the chi-squared 
test. A p<0.05 was considered to indicate statistically sig-
nificant differences. Statistical analysis was performed 
using STATA software (version 14.0; StataCorp, College 
Station, TX, USA).
Figure 1. (A) Multifocal stenosis of the proximal left pudendal artery (arrows) in a patient with erectile dysfunction. (B) Plain balloon 
angioplasty using a 3×40-mm balloon after the lesion had been crossed with a 0.014-inch guidewire. (C) Immediate angiographic 
results after plain balloon angioplasty showing the absence of residual arterial obstruction (arrows). (D) Early elastic recoil at 10 
minutes after plain balloon angioplasty (arrows). (E) Angiographic result after implantation of two 4×39-mm drug-eluting stents.
Table 1. Characteristics of 21 Patients Undergoing Endovascular Revascularization for Erectile Dysfunction Stratified by Treatment 
With Drug-Eluting Stent (DES) vs Drug-Coated Balloon (DCB).a
Total (n=21) DES (n=11) DCB (n=10) p
Age, y 58.3±9.3 57.7±8.0 59.1±11.5 0.732
Hyperlipidemia 8 5 3 0.466
Arterial hypertension 10 5 5 0.835
Diabetes mellitus 4 2 2 0.916
Coronary heart disease 4 2 2 0.916
Cerebrovascular disease 0 0 0 —
Peripheral artery disease 0 0 0 —
Smoking 14 8 6 0.537
 Current 9 6 3 0.256
 Former 5 2 3 0.525
Kidney disease 1 0 1 0.283
 Dialysis 0 0 0 —
Alcohol abuse 2 1 1 0.943
aContinuous data are presented as the mean ± standard deviation; categorical data are given as the number.
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Results
Technical success was obtained in all patients, and no com-
plications related to the primary safety endpoint were 
encountered. Mean MLD at baseline was 0.9±0.6 mm, 
which improved to 2.0±0.9 mm immediately after balloon 
dilation. At 10 minutes after dilation, the MLD was 
1.7±1.0 mm. Elastic recoil (lumen compromise >10%) 
was observed in all 31 lesions and resulted in a mean lumen 
compromise of 21.1%. Severe recoil (lumen compromise 
>30%) was observed in 14 arteries, resulting in a 36.3% 
reduction of the MLD.
DCB angioplasty was performed in 16 lesions using 
balloon diameters of 2.0, 2.5, 3.0, and 4.0 mm in 6, 4, 5, 
and 1 lesions, respectively. One flow-limiting dissection 
after DCB angioplasty was successfully treated with a 
DES. The 14 lesions with severe recoil were also treated 
with a DES. Stent diameters were 2, 2.5, 3, and 3.5 mm in 
1, 3, 10, and 1 lesions, respectively. During the 3-month 
follow-up, no TLR or TVR was performed.
Prior to revascularization, the mean baseline IIEF-15 
score of the 21 ED patients was 31.3±11.2, which improved 
to 49.8±16.8 at 3 months after revascularization (p<0.001). 
Accordingly, the scores for Question 3 improved from 
1.0±0.9 to 3.5±1.5 (p<0.002) and for Question 4 from 
0.8±0.6 to 2.9±1.7 (p<0.001) within the same interval. 
Further information on improvements in erectile function is 
provided in Table 3.
Discussion
The PANPI study6 was the first trial to describe angiographic 
characteristics of pelvic arterial obstructions in patients with 
suspected coronary artery disease and ED unresponsive to 
PDE-5 inhibitor therapy. In that study, arterial lesions in the 
internal pudendal artery exhibited atherosclerotic obstruc-
tions similar to those in the coronary arteries.
Since ED is mostly of arteriogenic origin, endovascular 
therapy for erection-related arteries has been recently shown 
to be feasible and safe.7,14 Still, the ideal antirestenotic 
Table 2. Angiographic Findings of the 31 Treated Lesions in 21 Erectile Dysfunction Patients Undergoing Endovascular Therapy.a
Variable Total (n=31) Pudendal Artery (n=27) Penile Artery (n=4) p
Lesion length, mm 20.6±13.9 23.0±13.3 4.0±1.6 0.008
Reference vessel diameter, mm 2.5±0.7 2.6±0.7 2.0±0.5 0.088
Minimum lumen diameter, mm 0.9±0.6 0.9±0.6 0.7±0.6 0.547
Minimum lumen diameter at baseline, mm 2.0±0.9 2.0±1.0 1.9±0.1 0.758
Minimum lumen diameter at 10 minutes, mm 1.7±1.0 1.6±1.0 1.9±0.1 0.658
Elastic recoil (>10%) 31 27 4 >0.99
Severe elastic recoil (>30%) 14 14 0 0.038
Drug-eluting stent 15 14 1 0.316
Drug-coated balloon 16 13 3 0.316
aContinuous data are presented as the mean ± standard deviation; categorical data are given as the number.
Table 3. Overview of Erectile Function in 21 Patients Undergoing Endovascular Revascularization for Erectile Dysfunction 
Comparing Drug-Eluting Stent (DES) vs Drug-Coated Balloon (DCB).a
Total (n=21) DES (n=11) DCB (n=10) pb
IIEF-15
 Baseline 31.3±11.2 30.4±15.6 32.2±12.2 0.726
 3 months 49.8±16.8 54.8±15.7 45.2±17.1 0.198
 Change over time 18.4±15.8 24.4±13.9 13.0±15.5 0.100
IIEF-15 Question 3c
 Baseline 1.0±0.9 1.3±0.9 0.6±0.7 0.078
 3 months 3.5±1.5 4.2±1.1 2.9±1.6 0.052
 Change over time 2.6±1.4 2.9±1.3 2.3±1.6 0.329
IIEF-15 Question 4d
 Baseline 0.8±0.6 0.9±0.6 0.7±0.6 0.525
 3 months 2.9±1.7 3.4±1.8 2.5±1.5 0.203
 Change over time 2.1±1.5 2.5±1.6 1.7±1.3 0.242
Abbreviation: IIEF, International Index of Erectile Function.
aData are presented as the mean ± standard deviation.
bBetween the DES and DCB subgroups.
Question 3c: When you attempted intercourse, how often were you able to penetrate (enter) your partner?
Question 4d: During sexual intercourse, how often were you able to maintain your erection after you had penetrated (entered) your partner?
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treatment for ED-related arteries, which are mostly smaller 
in diameter compared with tibial arteries, remains to be 
determined.7
Within the multicenter, single-arm ZEN trial,7 zotaroli-
mus-eluting stents were evaluated for the treatment of 45 
internal pudendal artery lesions in a total of 30 ED patients. 
The mean lesion length was 18.0 mm and the mean RVD in 
the pudendal artery was 2.6 mm. These morphological char-
acteristics are similar to the findings within the present 
study showing a mean lesion length and RVD of 20.6 mm 
and 2.5 mm, respectively. The procedural success rate was 
100% in the ZEN trial. During follow-up, no stent fractures 
were observed. However, angiographically verified binary 
restenosis (⩾50% lumen compromise) was reported to be 
34.4% at 6 months and thus much higher when compared 
with the restenosis rates of the same stent within the coro-
nary circulation.15
In the PERFECT-2 study, Wang et al14 reported outcomes 
of 22 patients undergoing endovascular therapy of the penile 
arteries, a more distally located arterial segment of even 
smaller diameter compared with the internal pudendal tract. In 
that study, plain balloon angioplasty for isolated penile artery 
stenosis was analyzed. Technical success was achieved in 
91% and the 8-month binary restenosis rate by CTA was 
41.2%. In a subsequent trial, the PERFECT-4 study, Wang 
et al16 randomized 44 ED patients undergoing angioplasty for 
penile arteries with an RVD ⩾1.5 mm to plain balloon angio-
plasty vs additional antirestenotic treatment with paclitaxel-
coated balloons. The RVD was 1.8 mm in the plain angioplasty 
group and 1.9 mm in the group treated with DCBs. At 8 
months, binary in-segment restenosis by CTA was 40% in the 
plain angioplasty group vs 48% in the DCB group.
Given that there were no significant differences in reste-
nosis rates comparing conventional angioplasty with DCB, 
elastic recoil may be the most important mechanism of fail-
ure subsequent to angioplasty of these small-caliber arter-
ies.9 To prevent elastic recoil, DES are recommended over 
bare metal stents based on the ZEN trial7 and our knowl-
edge obtained from tibial artery angioplasty,9 which has 
similar morphologies.
The mechanism of elastic recoil hampering endovas-
cular therapy has been reported in coronary10,17 and tibial 
arteries.9 Elastic recoil is a passive but dynamic contrac-
tion of the elastic compounds of the arterial wall; it leads 
to lumen compromise within minutes after balloon angio-
plasty and is associated with restenosis and an impair-
ment in clinical outcomes. Most coronary arteries are 
treated with a stent to prevent restenosis from elastic 
recoil. In erection-related arteries, the incidence of elastic 
recoil is even higher when compared with tibial arteries.9 
However, not all tibial lesions are treated with a stent. 
The average tibial lesion length is typically >8 cm,18 
which may serve as an explanation for the higher 
incidence of elastic recoil in the present study, with its 
relatively short lesions (mean 20.6 mm). In the present 
study, all lesions showing severe elastic recoil (>30%) 
were successfully treated with stents with the hope of 
maintaining patency over time. With the exception of one 
lesion with a flow-limiting dissection (treated with a 
DES), the lesions with mild elastic recoil were success-
fully treated with DCB angioplasty; interesting, there 
were no differences in the restenosis rate or clinical out-
comes compared to the patients treated with a stent, but 
the follow-up was very short. This finding may promote 
the “leave nothing behind” concept in these relatively 
young men (mean age 58 years) with ED.
The aforementioned ZEN study7 evaluated an improve-
ment of the IIEF score ⩾4 as a primary feasibility outcome, 
which was obtained in 59.3% at 6-month follow-up. The 
corresponding binary restenosis (⩾50% lumen compromise 
by angiography) rate was 34.4%. Based on these findings, 
DES of the pudendal arteries is considered safe and benefi-
cial for the majority of ED patients. Nevertheless, the rate 
of non-responders was rather high (40.7%), which may be 
attributed to the microangiopathy frequently observed in 
ED patients19 and to concomitant comorbidities.
In the PERFECT-4 study,16 about 80% of patients 
showed a direct clinical benefit immediately after revascu-
larization. However, at 12 months, only 50% to 60% of 
treated patients had a sustained erection benefit. Thus, both 
plain and DCB angioplasty were associated with moderate 
clinical success at 12 months.
Conclusion
Endovascular therapy for arteriogenic ED is a promising 
treatment concept and may be associated with a favorable 
short-term clinical response in a high subset of patients. 
Elastic recoil subsequent to plain balloon dilation of the 
pudendal artery is frequent and may contribute to restenosis 
in longer follow-up. Further studies are warranted to eluci-
date the ideal antirestenosis concept for these small-diame-
ter arteries.
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